Evaluation of the developmental toxicity of lenalidomide in rabbits

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 80, Issue 3, 2007, Pages 188-207

  Christian, Mildred S ^a   Laskin, Oscar L ^b   Sharper, Valerie ^c   Hoberman, Alan ^c   Stirling, David I ^b   Latriano, Louise ^b  

^a Argus International Inc   (United States)

^b CELGENE CORPORATION   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

Author keywords

Developmental toxicity; Lenalidomide; Rabbits; Safety; Teratogenicity; Thalidomide

Indexed keywords

LENALIDOMIDE; THALIDOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTOPSY; CHROMOSOME 5Q; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DRUG SENSITIVITY; FETUS MALFORMATION; FOOD INTAKE; GENE DELETION; LIMB MALFORMATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NIDATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; SAFETY; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; TOXICOKINETICS; WEIGHT REDUCTION;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; EMBRYONIC DEVELOPMENT; FEMALE; FETAL DEATH; FETUS; PREGNANCY; RABBITS; TERATOGENS; THALIDOMIDE;

ORYCTOLAGUS CUNICULUS;

EID: 34447277347     PISSN: 15429733     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrb.20115     Document Type: Article

References (60)

1. Bartlett JB, Dredge K, Dalgleish AG. 2004. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4:314-322.
2. Bartlett JB, Tozer A, Stirling D, Zeldis JB. 2005. Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide. Br J Cancer 93:613-619.
3. Beckmann R, Kampf HH. 1961. Zur quantitativen Bestimmung und zum qualitativen Nachweis von N-phthalyl-glutaminsaureimid (thalidomide). Arzneimittelforschung 11:45-57.
4. Brent RL, Holmes LB. 1988. Clinical and basic science lessons from the thalidomide tragedy: what have we learned about the causes of limb defects? Teratology 38:241-251.
5. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV. 2006. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108:618-621.
6. Christian MS. 2001. Test methods for assessing female reproductive and developmental toxicology. In: Hayes AW, editor. Principles and methods of toxicology. 4th Ed. Philadelphia: Taylor & Francis. p 1301-1381.
7. Christian MS, McCarty RJ, Cox-Sica DK, Cao CP. 1987. Recent increases in the incidence of skull, lung and rib alterations in vehicle control New Zealand white rabbits [Abstract 126]. J Am Coll Toxicol 6(4):562.
8. Corral LG, Haslett PA, Muller GW, Chen R, Wong L-M, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G. 1999. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-a. J Immunol 163:380-386.
9. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai Y-T, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC. 2001. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210-216.
10. DeParseval LM, Brady H, Verhelle D, Corral LG, Glezer E, Morris C, Chen R, Chan K. 2005. Lenalidomide and novel immunomodulatory drugs (IMiDs®): a new approach to the regulation of erythropoiesis and hemoglobin synthesis in anemia [abstract 2702]. ASH Annual Meeting Proceedings. Blood 106:759a(Part 1 of 2).
11. Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB. 2005. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69:56-63.
12. Dredge K, Marriott JB, Macdonald CD, Man H-W, Chen R, Muller GW, Stirling D, Dalgleish AG. 2002. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87:1166-1172.
13. Dunn OJ. 1964. Multiple comparisons using rank sums. Technometrics 6:241-252.
14. Dunnett CW. 1955. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 50:1121.
15. Fratta ID, Sigg EB, Maiorana K. 1965. Teratogenic effects of thalidomide in rabbits, rats, hamsters, and mice. Toxicol Appl Pharmacol 7:268-286.
16. Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI. 2006. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 30:849-858.
17. Haslett PA, Hanekom WA, Muller G, Kaplan G. 2003. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 187:946-955.
18. Hay M. 1964. Effects of thalidomide on pregnancy in the rabbit. J Reprod Fertil 8:59-76.
19. Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC. 2005. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 128:192-203.
20. Henry JB. 1996. Clinical diagnosis and management by laboratory methods. 19th Ed. Philadelphia: WB Saunders. p 636.
21. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai Y-T, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC. 2000. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943-2950.
22. Institute for Laboratory Animal Research. 1996. Guide for the care and use of laboratory animals.Washington, DC: National Academy Press.
23. Khera KS. 1981. Common fetal aberrations and their teratologic significance: a review. Fundam Appl Toxicol 1:13-18.
24. Khera KS. 1985. Maternal toxicity: a possible etiological factor in embryo-fetal deaths and fetal malformations of rodent-rabbit species. Teratology 31:129-153.
25. King CTG, Kendrick FJ. 1962. Teratogenic effects of thalidomide in the Sprague Dawley rat. Lancet 2:1116.
26. Kumar S, Rajkumar SV. 2006. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 42:1612-1622.
27. Lenz W. 1961. Kindliche Missbildungen nach Medikament wahrend der Gravidität. Deutsch Med Wochenschr 86:2555-2556.
28. Lenz W. 1985. Thalidomide embryopathy in Germany, 1959-1961. Prog Clin Biol Res 163C:77-83.
29. Lenz W. 1988. A short history of thalidomide embryopathy. Teratology 38:203-215.
30. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R. 2006. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456-1465.
31. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB. 2005. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549-557.
32. Liu M, Tanswell KA, Post M. 1999. Mechanical force-induced signal transduction in lung cells. Am J Physiol 277:L667-L683.
33. McBride WG. 1961. Thalidomide and congenital abnormalities. Lancet 2:1358.
34. Morgan GJ, Krishnan B, Jenner M, Davies FE. 2006. Advances in oral therapy for multiple myeloma. Lancet Oncol 7:316-325.
35. Muller GW, Chen R, Huang S-Y, Corral LG, Wong LM, Patterson RT, Chen Y, Kaplan G, Stirling DI. 1999. Amino-substituted thalidomide analogs: potent inhibitors of TNF-a production. Bioorg Med Chem Lett 9:1625-1630.
36. Nathan DG, Orkin SH. 1998. Nathan and Orkin's hematology of infancy and childhood. 5th Ed. Philadelphia: WB Saunders. p 730-739.
37. Nau H. 1995. Chemical structure-teratogenicity relationships, toxicokinetics and metabolism in risk assessment of retinoids. Toxicol Lett 82/83:975-979.
38. Neubert R, Neubert D. 1997. Peculiarities and possible mode of action of thalidomide. In: Kavlock RJ, Daston GP, editors. Handbook of experimental pharmacology. Drug toxicity in embryonic development: II. Vol. 124. Berlin: Springer-Verlag. p 41-119.
39. Nudleman KL, Travill AA. 1971. A morphological and histochemical study of thalidomide-induced upper limb malformations in rabbit fetuses. Teratology 4:409-425.
40. Parkhie M, Webb M. 1983. Embryotoxicity and teratogenicity of thalidomide in rats. Teratology 27:327-332.
41. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA. 2005. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:4050-4053.
42. Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man H-W, Schnetkamp PPM, Wolbring G, Govinda S, Corral LG, Payvandi F, Muller GW, Stirling DI. 2003. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 305:1222-1232.
43. Schardein JL. 1985. Chemically induced birth defects. New York: Marcel Dekker. p 215-239.
44. Shepard TH. 1989. Catalog of teratogenic agents. 6th Ed. Baltimore: John Hopkins University Press. p 608-612.
45. Siegel S. 1956. The Fisher's exact probability test. In: Nonparametric statistics for the behavioral sciences. New York: McGraw-Hill. p 96-105.
46. Snedecor GW, Cochran WG. 1967a. Analysis of variance. In: Statistical methods. 6th Ed. Ames, IA: Iowa State University Press. p 258-298.
47. Snedecor GW, Cochran WG. 1967b. Variance test for homogeneity of the binomial distribution. In: Statistical methods. 6th Ed. Ames, IA: Iowa State University Press. p 240-241.
48. Sokal RR, Rohlf FJ. 1969a. Bartlett' s test of homogeneity of variances. In: Biometry: the principles and practice of statistics in biological research. San Francisco: Freeman & Co. p 370-371.
49. Sokal RR, Rohlf FJ. 1969b. Kruskal-Wallis test. In: Biometry: the principles and practice of statistics in biological research. San Francisco: Freeman & Co. p 388-391.
50. Somers G. 1962. Thalidomide and congenital abnormalities. Lancet 1: 912-913.
51. Staples R. 1974. Detection of visceral alterations in mammalian fetuses. Teratology 9:A37-A38.
52. Staples R, Schnell V. 1964. Refinements in rapid clearing technic in the KOH-alizarin red S method for fetal bone. Stain Technol 39:61-63.
53. Teitel DF. 1996. Fetal chemoreception: a developing story. Reprod Fertil Dev 8:471-482.
54. Teo SK, Denny KH, Stirling DI, Thomas SD, Morseth S, Hoberman AM. 2004. Effects of thalidomide on developmental, peri- and postnatal function in female New Zealand white rabbits and offspring. Toxicol Sci 81:379-389.
55. United States Food and Drug Administration. 1987. Good laboratory practice regulations. Final Rule 21 CFR Part 58.
56. United States Food and Drug Administration. 1994. International Conference on Harmonization. Guideline on detection of toxicity to reproduction for medicinal products. V59, No. 183.
57. Wu A, Scheffler MR. 2004. Multiple-dose pharmacokinetics and safety of CC-5013 in 15 multiple myeloma patients [abstract 2056]. Proceedings of the American Society of Clinical Oncology. 23:141.
58. Zambrana MA, Greenwald GS. 1971. Effects of fetal ovarian and placental weight of various number of fetuses in the rat. Biol Reprod 4:216-223.
59. Zeldis JB, Williams BA, Thomas SD, Elsayed ME. 1999. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 21:319-330.
60. Zhang L-H, Lu L, Wu L, Dredge K, Bartlett JB, Schafer P, Muller G, Dalgleish A, Stirling D. 2005. Comparison of anti-angiogenic activities of thalidomide and lenalidomide in vitro [abstract 3959]. Blood 106:69b. (Part 1 of 2).